Plant Name: Justicia hayatai
Taxonomic Information:
Plant ID: NPO998
Plant Latin Name: Justicia hayatai
Taxonomy Genus: Justicia
Taxonomy Family: Acanthaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| NPSR1; | |
| RECQL; TDP1; GLO1; ALOX12; HSD17B1; HPGD; AKR1B1; HSD17B2; HSD17B10; NOX4; APEX1; POLB; | |
| ACHE; | |
| TOP2A; | |
| TEK; INSR; AXL; MET; FLT3; CDK1; EGFR; PIM1; SRC; KDR; IGF1R; AURKB; CSNK2A1; NUAK1; | |
| CA12; CA7; CA4; | |
| ESR2; | |
| KDM4E; | |
| TYR; | |
| AHR; | |
| FUT7; | |
| SLC22A6; | |
| SMAD3; LMNA; THPO; HSPA1A; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 1.166E-10 | 1.493E-07 | AKR1B1, ALOX12, AURKB, AXL, CDK1, CSNK2A1, EGFR, GLO1, HSPA1A, IGF1R, KDR, LMNA, PIM1, SMAD3, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 3.532E-09 | 2.481E-06 | AXL, EGFR, INSR, MET, NOX4, SRC, TEK, THPO |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 4.119E-08 | 1.692E-05 | AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK, TOP2A |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.672E-08 | 3.096E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.085E-07 | 3.634E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.870E-07 | 6.944E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 4.099E-07 | 9.496E-05 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 7.353E-07 | 1.482E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4, SRC |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.197E-06 | 2.254E-04 | EGFR, INSR, KDR |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.238E-06 | 2.285E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.707E-06 | 3.124E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 2.162E-06 | 3.890E-04 | ACHE, EGFR, HSD17B1, IGF1R, INSR |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 3.862E-06 | 6.469E-04 | ACHE, APEX1, CSNK2A1, EGFR, FLT3, IGF1R, INSR, KDR, L3MBTL1, PIM1, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 4.047E-06 | 6.677E-04 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 4.096E-06 | 6.706E-04 | AKR1B1, APEX1, CSNK2A1, CYP1A2, EGFR, FLT3, HPGD, INSR, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 6.047E-06 | 9.229E-04 | APEX1, POLB |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.417E-06 | 9.570E-04 | CA12, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 8.959E-06 | 1.309E-03 | EGFR, KDR, NOX4, SRC, TEK, THPO |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.043E-05 | 1.446E-03 | CDK1, EGFR, IGF1R, INSR |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 1.382E-05 | 1.869E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.735E-05 | 2.304E-03 | EGFR, IGF1R, INSR, KDR, TEK |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.856E-05 | 2.406E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 2.211E-05 | 2.783E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.463E-05 | 3.013E-03 | CYP1A1, CYP1A2, CYP1B1 |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 2.615E-05 | 3.181E-03 | ACHE, AKR1B1, APEX1, CA4, EGFR, HSPA1A, NOX4, SRC, TYR |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.724E-05 | 3.295E-03 | ACHE, CSNK2A1, EGFR, ESR2, FLT3, HPGD, IGF1R, KDR, L3MBTL1, MET, SLC22A6, SMAD3, TOP2A, TYR |
| BP | GO:0032502; developmental process | GO:0048732; gland development | 2.872E-05 | 3.398E-03 | CSNK2A1, CYP19A1, EGFR, INSR, SMAD3, TYR |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 3.077E-05 | 3.602E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.617E-05 | 4.123E-03 | CYP1A1, CYP1A2 |
| BP | GO:0040007; growth | GO:0045927; positive regulation of growth | 3.849E-05 | 4.320E-03 | ALOX12, CDK1, CSNK2A1, EGFR, INSR, PIM1 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 4.198E-05 | 4.571E-03 | CYP1A1, LMNA, NOX4, SMAD3, SRC, TEK |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 4.670E-05 | 5.009E-03 | CDK1, EGFR, FLT3, INSR, NOX4, SRC |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.704E-05 | 5.021E-03 | ALOX12, CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 5.029E-05 | 5.230E-03 | AXL, IGF1R, INSR |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 5.578E-05 | 5.675E-03 | FLT3, SRC, TEK |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 6.790E-05 | 6.542E-03 | AHR, CSNK2A1, KDR |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 7.000E-05 | 6.702E-03 | AHR, AXL, CSNK2A1, EGFR, SRC, TOP2A |
| BP | GO:0002376; immune system process | GO:0030097; hemopoiesis | 7.018E-05 | 6.702E-03 | FLT3, KDR, L3MBTL1, TEK |
| MF | Unclassified; | GO:0004872; receptor activity | 7.548E-05 | 7.115E-03 | AHR, AXL, EGFR, ESR2, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, TEK |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 8.013E-05 | 7.521E-03 | ACHE, CDK1, CYP1A1, EGFR, SMAD3 |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 8.314E-05 | 7.704E-03 | EGFR, INSR, KDR, SLC22A6, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 9.013E-05 | 8.211E-03 | ALOX12, HPGD |
| BP | GO:0050896; response to stimulus | GO:0051591; response to cAMP | 9.427E-05 | 8.549E-03 | APEX1, NOX4, TEK, TYR |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 9.602E-05 | 8.640E-03 | CA4, EGFR, HPGD, SLC22A6, TEK |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.707E-05 | 8.698E-03 | CA12, CA4, CA7 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.683E-11 | 3.327E-09 | HSD17B1, INSR, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 4.630E-10 | 2.871E-08 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.092E-09 | 2.105E-07 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 6.718E-07 | 2.083E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 2.636E-06 | 6.537E-05 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.649E-05 | 2.921E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 9.299E-05 | 1.273E-03 | SRC, EGFR, ESR2, HSPA1A |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.232E-04 | 1.273E-03 | SRC, KDR, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.578E-04 | 1.505E-03 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.203E-04 | 1.273E-03 | SRC, KDR, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.085E-04 | 1.273E-03 | INSR, TEK, EGFR, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.204E-04 | 1.273E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.899E-04 | 2.568E-03 | SMAD3, INSR, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 4.228E-04 | 3.495E-03 | THPO, FLT3, KDR, MET, EGFR |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 6.041E-04 | 3.942E-03 | FUT7, HSD17B1, HSD17B2, CYP1A2, CYP1A1, AKR1B1, ALOX12, TYR, CYP19A1, HSD17B10 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.616E-06 | 1.781E-04 | CA12, CA4, CA7 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 4.877E-04 | 3.780E-03 | INSR, HSPA1A, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 5.580E-04 | 3.942E-03 | FLT3, MET, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 5.827E-04 | 3.942E-03 | SRC, MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 6.612E-04 | 4.100E-03 | MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 9.065E-04 | 5.109E-03 | HPGD, FLT3, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.172E-04 | 4.235E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.234E-03 | 6.375E-03 | SRC, CDK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.006E-03 | 5.423E-03 | CYP1A2, CYP1A1, CYP1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| NA: NA | GIST | NA | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; TEK; EGFR; SRC; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; SRC; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; INSR; EGFR; CYP19A1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; INSR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; TEK; EGFR; SRC; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
